Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -9 of 9
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Active
18 and over
Pharmaceutical / Industry
20040212
NCT00109031
2.
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care, Treatment
Active
18 to 70
Pharmaceutical / Industry
20050219
NCT00434161
3.
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Palifermin (rHuKGF) in the Reduction of Acute Graft Versus Host Disease in Subjects With Hematologic Malignancies Undergoing Allogeneic Marrow/PBPC Transplantation
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Supportive care
Active
18 and over
Pharmaceutical / Industry
20040213
NCT00189488
4.
Palifermin After Haploidentical PBSCT
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Approved-not yet active
18 to 65
Other
EudraCt: 2007-003241-32
NCT00570999
First Published:
8/4/2008
5.
Phase II Randomized Study of Palifermin in Preventing Chemotherapy- and/or Radiotherapy-Induced Oral Mucositis in Pediatric Patients Undergoing Autologous or Allogeneic Hematopoietic Stem Cell Transplantation
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Supportive care, Treatment
Approved-not yet active
1 to 16
NCI
COG-ACCL0521
ACCL0521, COG-ACCL0521, NCT00728585
6.
Busulfan, Melphalan, and Fludarabine With Peri-Transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Supportive care, Treatment
Active
Under 65
Other
08-008
NCT00629798
7.
A Phase 1 Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
1 to 16
Pharmaceutical / Industry
20010133
NCT00460421
Last Modified:
8/23/2008
 
First Published:
5/23/2007
8.
Phase I Pilot Study of High-Dose Melphalan and Palifermin in Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation for Stage II or III Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Supportive care, Treatment
Active
18 and over
NCI
WSU-2006-119
WSU 2006-119, NCT00482846
9.
Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Supportive care
Active
2 to 18
Other
PALSCT
NCT00701688
Select All on One Page
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute